Abstracts tagged "Biologicals"

Abstract Number: 1363 • ACR Convergence 2020
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
Vibeke Strand¹, Gurjit Kaeley², Martin Bergman³, Dafna Gladman⁴, Laura Coates⁵, Peter Hur⁶, Nina Kim⁷, Bhumik Parikh⁶, Patricia Pertel⁸ and Philip Mease⁹, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Oxford, Oxford, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁸Novartis AG, Basel, Switzerland, ⁹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…
Abstract Number: 1630 • ACR Convergence 2020
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Lars Iversen¹, Christopher EM Griffiths², Andrea Peserico³, Ignasi Pau-Charles⁴, Andrew Blauvelt⁵, Diamant Thaçi⁶ and Kristian Reich⁷, ¹Aarhus University Hospital, Aarhus, Denmark, ²The University of Manchester, Manchester, United Kingdom, ³DIMED University of Padua, Padua, Italy, ⁴Almirall R&D, Barcelona, Spain, ⁵Oregon Medical Research Center, Portland, OR, ⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation®, Hamburg, Germany
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody that is approved for the treatment of moderate to severe plaque psoriasis. The objective of this…
Abstract Number: 2017 • ACR Convergence 2020
Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis
Philip Mease¹, Désirée van der Heijde², Bruce Kirkham³, Georg Schett⁴, Ana-Maria Orbai⁵, Christopher Ritchlin⁶, Joseph Merola⁷, Luminita Pricop⁸, Xuan Zhu⁹, DavidA James⁹ and Gregory Ligozio⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Novartis Pharmaceuticals Corporation, East Hanover, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Assessment of radiographic joint damage extent and progression is important in clinical trials evaluating treatments for psoriatic arthritis (PsA). Joint damage in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].